Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...

The primary goal of depot somatostatin-analogue (SSA) therapy for acromegaly is to reduce disease activity by suppressing growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion. A test ...

This was a 48-week, international, open-label, prospective trial of octreotide LAR. Eligible participants were aged 18–80 years with a biochemical diagnosis of acromegaly. Patients who had already ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. As Healio previously reported, more than 90% of ...

BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study Forty-two patients with advanced thymoma or thymic ...

Credit: Getty Images. The NETTER-2 trial included patients with newly diagnosed SSTR-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors. First-line treatment with lutetium ...

May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...

October 12, 2012 (Montreal, Quebec) — In a finding described as both surprising and practice-changing, octreotide (Sandostatin, Novartis) showed no benefit over less expensive, more accessible ...

Researchers at the Medical University of South Carolina revealed the need to clarify current treatment guidelines for octreotide therapy following an esophageal variceal hemorrhage in a recent study ...

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. Diarrhea is one of the dose-limiting toxicities for administration of ...